Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile (MEDA)

March 22, 2013 updated by: AAstrup, University of Copenhagen

Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile in Urine and Plasma in Overweight Adults

The purpose of this randomized, controlled, cross over single meal study is to investigate the metabolic effects of a breakfast rich in dairy proteins and to determine biomarkers for their intake. The results from this project will increase our knowledge about nutritional value of dairy proteins, which is necessary to decide whether dairy products can be recommended for prevention of weight related bone loss.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

17

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Frederiksberg C
      • Copenhagen, Frederiksberg C, Denmark, 1958
        • Department of Human Nutrition, University of Copenhagen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy males and females between 18 and 50 years
  • BMI 25-40

Exclusion Criteria:

  • Physical activity more than 10 hours weekly
  • Smoking
  • Diagnosed osteoporosis in at least one parent
  • Dietary supplements and vitamin pills (during the study and 2 months before the start)
  • Vegetarians and vegans
  • Lactose intolerant
  • Women who are pregnant, breastfeeding or post-menstrual
  • Regular intake of medication
  • Chronic diseases (including osteoporosis, cancer, diabetes, cardiovascular disease and mental disorders)
  • Participation in other clinical trials that could affect the test results
  • Donation of blod within 3 months before intervention start
  • Hypersensitivity to paraaminobenzoic acid (PABA)
  • Not able to comply with the procedures established by the Protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Meal rich in dairy protein
Test meals with different protein types (dairy versus meat)
Experimental: Meal rich in meat protein
Test meals with different protein types (dairy versus meat)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
serum C-terminal carboxy-terminal collagen crosslinks (CTX)
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
urine C-terminal carboxy-terminal collagen
Time Frame: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
serum osteocalcin (sOC)
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
serum tartrate-resistant acid phosphatase (s-TRAP)
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
urine deoxypyridinoline crosslink (uDPD)
Time Frame: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
plasma metabolites for metabolomics analyses
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
urine metabolites for metabolomics analyses
Time Frame: baseline 24-h urine samples, 24-h urine samples after the meal test, urine samples at 2-h and 4-h after the meal test and urine samples from 4-h to 24-h, all at both visits
baseline 24-h urine samples, 24-h urine samples after the meal test, urine samples at 2-h and 4-h after the meal test and urine samples from 4-h to 24-h, all at both visits

Secondary Outcome Measures

Outcome Measure
Time Frame
serum insulin-growth factor-1 (IGF-1)
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
serum insulin-growth factor binding-protein-3 (IGFBP-3)
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
serum insulin
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
serum glucose
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
serum glukagon-like peptide-1 (GLP-1)
Time Frame: at 0, 30, 60, 120, 180 and 240 min at both visits
at 0, 30, 60, 120, 180 and 240 min at both visits
urinary PABA
Time Frame: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
urinary creatinin
Time Frame: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
urinary biobank
Time Frame: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
plasma biobank
Time Frame: at 0, 30, 60, 90, 120, 180 and 240 min at both visits
at 0, 30, 60, 90, 120, 180 and 240 min at both visits

Other Outcome Measures

Outcome Measure
Time Frame
weight
Time Frame: at baseline at both visits
at baseline at both visits
height
Time Frame: at baseline at the first visit
at baseline at the first visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2012

Primary Completion (Actual)

February 1, 2013

Study Completion (Actual)

February 1, 2013

Study Registration Dates

First Submitted

January 15, 2013

First Submitted That Met QC Criteria

January 22, 2013

First Posted (Estimate)

January 23, 2013

Study Record Updates

Last Update Posted (Estimate)

March 25, 2013

Last Update Submitted That Met QC Criteria

March 22, 2013

Last Verified

March 1, 2013

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Dietary meal intervention

Subscribe